Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT

Lawrence Einhorn, Mary J. Brames, Michael C. Heinrich, Christopher L. Corless, Ali Madani

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

OBJECTIVE: This phase II study was conducted to determine the activity of imatinib (gleevec) in heavily pretreated patients with KIT-positive metastatic germ cell tumor. MATERIALS AND METHODS: From June 2002 through April 2005, 18 patients with refractory germ cell tumors were tested for KIT expression by immunohistochemistry. All patients screened were deemed to be incurable with further standard chemotherapy or surgery. Six patients were eligible and treated with imatinib 600 mg/d orally. RESULTS: There were no complete or partial remissions. Five of 6 patients had progressive disease and 1 patient had stable disease with a >50% decline in serum alpha-fetoprotein for 3 months before developing further progression. CONCLUSION: In this small sample size, there was no evidence of significant antitumor activity of imatinib in patients with KIT-positive refractory germ cell tumors.

Original languageEnglish
Pages (from-to)12-13
Number of pages2
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume29
Issue number1
DOIs
StatePublished - Feb 2006

Fingerprint

Germ Cell and Embryonal Neoplasms
Drug Therapy
alpha-Fetoproteins
Imatinib Mesylate
Sample Size
Immunohistochemistry
Serum

Keywords

  • Germ cell tumor
  • Imatinib
  • KIT

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. / Einhorn, Lawrence; Brames, Mary J.; Heinrich, Michael C.; Corless, Christopher L.; Madani, Ali.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 29, No. 1, 02.2006, p. 12-13.

Research output: Contribution to journalArticle

Einhorn, Lawrence ; Brames, Mary J. ; Heinrich, Michael C. ; Corless, Christopher L. ; Madani, Ali. / Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2006 ; Vol. 29, No. 1. pp. 12-13.
@article{a76c3fe60f5444c7a9c358012138ca94,
title = "Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT",
abstract = "OBJECTIVE: This phase II study was conducted to determine the activity of imatinib (gleevec) in heavily pretreated patients with KIT-positive metastatic germ cell tumor. MATERIALS AND METHODS: From June 2002 through April 2005, 18 patients with refractory germ cell tumors were tested for KIT expression by immunohistochemistry. All patients screened were deemed to be incurable with further standard chemotherapy or surgery. Six patients were eligible and treated with imatinib 600 mg/d orally. RESULTS: There were no complete or partial remissions. Five of 6 patients had progressive disease and 1 patient had stable disease with a >50{\%} decline in serum alpha-fetoprotein for 3 months before developing further progression. CONCLUSION: In this small sample size, there was no evidence of significant antitumor activity of imatinib in patients with KIT-positive refractory germ cell tumors.",
keywords = "Germ cell tumor, Imatinib, KIT",
author = "Lawrence Einhorn and Brames, {Mary J.} and Heinrich, {Michael C.} and Corless, {Christopher L.} and Ali Madani",
year = "2006",
month = "2",
doi = "10.1097/01.coc.0000195086.47548.ef",
language = "English",
volume = "29",
pages = "12--13",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT

AU - Einhorn, Lawrence

AU - Brames, Mary J.

AU - Heinrich, Michael C.

AU - Corless, Christopher L.

AU - Madani, Ali

PY - 2006/2

Y1 - 2006/2

N2 - OBJECTIVE: This phase II study was conducted to determine the activity of imatinib (gleevec) in heavily pretreated patients with KIT-positive metastatic germ cell tumor. MATERIALS AND METHODS: From June 2002 through April 2005, 18 patients with refractory germ cell tumors were tested for KIT expression by immunohistochemistry. All patients screened were deemed to be incurable with further standard chemotherapy or surgery. Six patients were eligible and treated with imatinib 600 mg/d orally. RESULTS: There were no complete or partial remissions. Five of 6 patients had progressive disease and 1 patient had stable disease with a >50% decline in serum alpha-fetoprotein for 3 months before developing further progression. CONCLUSION: In this small sample size, there was no evidence of significant antitumor activity of imatinib in patients with KIT-positive refractory germ cell tumors.

AB - OBJECTIVE: This phase II study was conducted to determine the activity of imatinib (gleevec) in heavily pretreated patients with KIT-positive metastatic germ cell tumor. MATERIALS AND METHODS: From June 2002 through April 2005, 18 patients with refractory germ cell tumors were tested for KIT expression by immunohistochemistry. All patients screened were deemed to be incurable with further standard chemotherapy or surgery. Six patients were eligible and treated with imatinib 600 mg/d orally. RESULTS: There were no complete or partial remissions. Five of 6 patients had progressive disease and 1 patient had stable disease with a >50% decline in serum alpha-fetoprotein for 3 months before developing further progression. CONCLUSION: In this small sample size, there was no evidence of significant antitumor activity of imatinib in patients with KIT-positive refractory germ cell tumors.

KW - Germ cell tumor

KW - Imatinib

KW - KIT

UR - http://www.scopus.com/inward/record.url?scp=33644864408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644864408&partnerID=8YFLogxK

U2 - 10.1097/01.coc.0000195086.47548.ef

DO - 10.1097/01.coc.0000195086.47548.ef

M3 - Article

VL - 29

SP - 12

EP - 13

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -